RARX stock forecast
Our latest prediction for Ra Pharmaceuticals, Inc.'s stock price was made on the Dec. 14, 2018 when the stock price was at 16.29$.
In the short term (2weeks), RARX's stock price should outperform the market by 4.18%. During that period the price should oscillate between -9.03% and +14.48%.
In the medium term (3months), RARX's stock price should outperform the market by 5.45%. During that period the price should oscillate between -19.77% and +33.01%.Get email alerts
About Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. The company's product include RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria. Ra Pharmaceuticals was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.
At the moment the company generates 6M USD in revenues.
On its last earning announcement, the company reported a loss of -1.98$ per share.
The book value per share is 2.94$
Three months stock forecastDec. 14, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|